IPSC · Century Therapeutics Inc
United States · RS rating 42 · As of 2026-11-03
| Price | 1.52 USD |
|---|---|
| 1-day change | +2.7% |
| RS rating (overall / 1M / 3M / 12M) | 42 / 65 / 28 / 97 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 25 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -54.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +48.3% |
| Market cap (USD) | $406.2M |